SCHEMBL2608532

SCHEMBL2608532

CC(C)(C)OC(=O)NC(C(=O)N1CCC(O)CC1)c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.45
POLB P06746 1/20 0.44
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
PRSS1 P07477 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
KDM4D Q6B0I6 1/20 0.40
MAPK1 P28482 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MMP13 P45452 1/20 0.40
CTSS P25774 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21180503 0.85 TACR1 (0.50) PABPC1POLBKMT2AMEN1ALDH1A1
SCHEMBL17883715 0.82 CTSS (0.49) F2F10PRSS1KMT2AMAPK1
SCHEMBL2107052 0.81 PABPC1 (0.63) PABPC1POLBKMT2AMAPK1ALDH1A1
SCHEMBL2107050 0.81 PABPC1 (0.63) PABPC1POLBKMT2AMAPK1ALDH1A1
SCHEMBL2107346 0.81 PABPC1 (0.63) PABPC1POLBKMT2AMAPK1ALDH1A1
SCHEMBL863961 0.79 DPP4 (0.42) MAPK1NPC1ALDH1A1MAPTHTT
SCHEMBL863962 0.79 DPP4 (0.42) MAPK1NPC1ALDH1A1MAPTHTT
SCHEMBL29527431 0.78 CTSK (0.57) F2F10PRSS1KMT2AMAPK1
SCHEMBL16171661 0.77 CTSS (0.49) KMT2AMEN1MAPTHTTCTSS
SCHEMBL16174131 0.77 CTSS (0.49) KMT2AMEN1MAPTHTTCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158622-B2 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2012-04-17 US disclosed
US-20090023703-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023703-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PYGL, PYGM, PYGB PABPC1 1305/4885POLB 483/4885F2 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.